NV1020

DB04969InvestigationalGene Therapies

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

Mechanism
Curator reviewed
Primary indication
Intended for the treatment of various forms of cancer.Curator reviewed
Code names
NV1020

What you can answer from here — as of October 01, 2026

2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of NV1020, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account